A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.

However, as shown in Cluster 1, when the SP120 antibody is used in combination with 10D7G2, over 40% of cases that were classified as hENT1 High with the 10D7G2 antibody have only a slight sensitivity to adjuvant gemcitabine which failed to reach statistical significance on univariable analysis.

also in 6,035 other papers

Multivariable DSS analysis on all three clusters to ascertain tumoural sensitivity to adjuvant gemcitabine showed that the borderline significance found in Cluster 1 in the univariable approach became statistically significant in the context of the addition of regional lymph node status and lymphovascular invasion with a risk ratio of 0.52 and 95% confidence interval of 0.28–0.94.

also in 7,017 other papers